Major Drugmaker Loses $27 Billion After Heart Disease Drug Fails Phase III Trial

Two pharmaceutical companies announced that their jointly developed heart disease drug failed its Phase III trial, leading to a significant loss of $27 billion in market value for a major drugmaker.

9 Jul, 09:53 — 9 Jul, 09:53

Post Share

Sources

Showing 1 of 1 sources

marketwatchMostly Factual54d ago

Major drugmaker loses $27 billion in market value after failed trial

Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.

By Nora Redmond

Read full article →

Major Drugmaker Loses $27 Billion After Heart Disease Drug Fails Phase III Trial

Sources

Major drugmaker loses $27 billion in market value after failed trial

Related Stories

Nvidia Nears $14 Billion Acquisition Deal for AI Startup Hugging Face

US-Iran Strikes Trigger Oil Surge and Global Market Volatility

Bessent Defends Economic Pressure Strategy Against Iran and Tariff Proposals

Casablanca Airport Sets Daily Passenger Record Amid Summer Travel Surge